Research programme: complement factor 5a inhibitors - Neurogen

Drug Profile

Research programme: complement factor 5a inhibitors - Neurogen

Alternative Names: Research programme: C5a receptor inhibitors - Neurogen

Latest Information Update: 06 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Class Small molecules
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 06 Jul 2010 Development discontinued during 2008
  • 25 Apr 2007 No development reported - Preclinical for Inflammation in USA (unspecified route)
  • 16 Jun 2004 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top